Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in treatment-resistant axial spondyloarthritis
ChiCTR2600133149Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of bimekizumab in axial spondyloarthritis (axSpA) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: ASAS40 response rate at Week 16. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2600133149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133149.